Acute tubular necrosis after selective FGFR tyrosine kinase inhibitor therapy

In the field of medical oncology, targeted therapies have greatly improved the prognosis of patients but renal side-effects have progressively emerged, leading to drug withdrawal that may negatively impact optimal therapeutic management and oncological outcome [ [1] Sassier M. Dugué A.E. Clarisse B. Lesueur P. Avrillon V. Bizieux-Thaminy A. et al. Renal insufficiency is the leading cause of double maintenance (bevacizumab and pemetrexed) discontinuation for toxicity to advanced non-small cell lung cancer in real world setting. Lung Canc. 2015; 89: 161-166https://doi.org/10.1016/j.lungcan.2015.05.005 Abstract Full Text Full Text PDF PubMed Scopus (16) Google Scholar ].